About VectorBuilder
VectorBuilder is a company based in Chicago (United States) founded in 2014. VectorBuilder has raised $57.15 million across 1 funding round from investors including Xiamen C&D Metals, Legend Capital and Yuexiu Capital. VectorBuilder operates in a competitive market with competitors including Genezen, 3PBiovian, Oxford Biomedica Solutions, Ascend and Yaunxing Gene Technology, among others.
- Headquarter Chicago, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$57.15 M (USD)
in 1 rounds
-
Latest Funding Round
$57.15 M (USD), Series C
Oct 13, 2022
-
Investors
Xiamen C&D Metals
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of VectorBuilder
Unlock access to complete
Funding Insights of VectorBuilder
VectorBuilder has successfully raised a total of $57.15M through 1 strategic funding round. The most recent funding activity was a Series C round of $57.15 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in VectorBuilder
VectorBuilder has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Xiamen C&D Metals, Legend Capital and Yuexiu Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture Capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Yuexiu Capital is engaged in financial services and asset management.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for VectorBuilder
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by VectorBuilder
Investment portfolio details for VectorBuilder
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - VectorBuilder
Detailed financials for VectorBuilder
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vectorbuilder Comparisons
Peer comparison for VectorBuilder
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of VectorBuilder
VectorBuilder operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Genezen, 3PBiovian, Oxford Biomedica Solutions, Ascend and Yaunxing Gene Technology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
CDMO focused on manufacturing of viral vector products
|
|
| Locked | Locked | Locked |
CDMO focused on developing viral vectors
|
|
| Locked | Locked | Locked |
Oxford Biomedica Solutions is a CDMO focused on manufacturing AAV cell and gene therapy products.
|
|
| Locked | Locked | Locked |
Online insurance payments and premium financing are enabled for businesses.
|
|
| Locked | Locked | Locked |
Provider of gene therapy drugs and viral vector and mRNA drug CDMO services
|
Detailed competitors of VectorBuilder
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vectorbuilder
Complete news archive for VectorBuilder
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VectorBuilder
VectorBuilder was founded in 2014 and raised its 1st funding round 8 years after it was founded.
VectorBuilder is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
VectorBuilder is a funded company, having raised a total of $57.15M across 1 funding round to date.
VectorBuilder was founded in 2014 in Chicago, United States, within the biotechnology sector. An online platform is maintained for vector design, custom cloning, and virus packaging services. These encompass lentivirus, adenovirus, adeno-associated virus (AAV), MMLV, and piggyBac systems. Operations focus on facilitating research and development needs for scientific applications across global users.
VectorBuilder has 5 investors. Key investors include Xiamen C&D Metals, Legend Capital, Yuexiu Capital, China Chengtong, and Wanlian Tianze.